Evidence strategy
OXON helps clients to identify and fill in the data gaps for their products in the pre-and post approval phases.
We work with clients, based on their strategy, using the appropriate components illustrated bellow:
We provide the highest quality appropriate interpretation presented apropriately for the target audience.
We help decision making for clients in development and post-marketing phases by building appropriate decision models.
Our expertise of the review, synthesis and integration of data and information is of the highest standard:
Senior members of OXON have co-authored (x7) Lancet, (x1) JAMA and (x3) BMJ publications of individual-participant and grouped data meta-analyses of epidemiological studies and trials
A senior member of OXON was the founding co-ordinating editor of the Cochrane Dementia Group
A senior member of OXON is chief editor of the international clinical textbook 'Evidence-based Dementia Practice'. published by Blackwells, Oxford. We are leading an initiative in ENCePP at the EMA on data integration, the first task of which will be a guidance document on the conduct of data integration of observational studies, with leading academic epidemiologists and regulators in Europe.
-
Expertise in epidemiology and trials and meta-analysis
We have published in the top medical major journals ((x7) Lancet, (x1) JAMA and (x3) BMJ), led a Cochrane group, have an honorary senior lecturer in epidemiology at Imperial College, London University, and are currently leading an initiative at the EMA on data integration for safety
-
Expertise in statistics:
We have analysed epidemiological, trials, safety, PRO, health economic data. We have access to academic statisticians in Cambridge and London (a world renowned medical statistician) as consultants.
-
Clinical (and patient-reported outcomes) expertise:
We have an Oxford trained honorary consultant geriatrician and a patient-reported outcomes researcher, rapid access to practising hospital clinical consultants in a range of therapeutic areas and also an Oxford professor of patient reported outcomes as a consultant.
-
Pharmacovigilance expertise:
We have a former head of PV at Schering-Plough, have contacts at the EMA and also a former Director of the WHO Drug Monitoring Centre and member of CIOMS acts as a consultant.
-
Knowledge of industry
Members of OXON have previously worked in big pharma at varying levels of seniority (SB, GSK, Pfizer, Pharmacia, AstraZeneca, Schering-Pough) and have an intimate knowledge of the workings of industry, which they bring to bear in finding solutions for clients.
Copyright © 2013 Oxon All Rights Reserved - Late phase CRO